-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 I8kEZD9PvaRaUkjuVFnHfgotjBEcS8qslnNP9mA7i2zjzS+bOavHwNlqaJCyGg7C
 Jlynu3NcX1uqMMfaaZLCmg==

<SEC-DOCUMENT>0001144204-07-030610.txt : 20070606
<SEC-HEADER>0001144204-07-030610.hdr.sgml : 20070606
<ACCEPTANCE-DATETIME>20070606171108
ACCESSION NUMBER:		0001144204-07-030610
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070606
FILED AS OF DATE:		20070606
DATE AS OF CHANGE:		20070606

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		07904696

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT WEIZMANN BUILDING 3
		CITY:			REHOVOT76100 ISRAEL
		STATE:			L3

	MAIL ADDRESS:	
		STREET 1:		KIRYAT WEIZMANN BUILDING 3
		CITY:			REHOVOT76100 ISRAEL
		STATE:			L3
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v077700_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div>&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16 </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      June
      6, 2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>XTL
      Biopharmaceuticals Ltd.</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>750
      Lexington Avenue, 20</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>th</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      Floor</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>New
      York, New York 10022</u></strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x&#160;&#160;
</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      40-F
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
<font style="FONT-FAMILY: Wingdings">o&#160;&#160;
</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No
<font style="FONT-FAMILY: Wingdings">x</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      N/A</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div>&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><img src="xtlbio.jpg" alt=""></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
      Provides Update on Phase I Clinical Trial of XTL-2125 </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Valley
      Cottage, New York, June 6, 2007</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      -- XTL
      Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announced today
      that
      it has completed the analysis of results from a Phase I clinical trial with
      XTL-2125 in patients with chronic Hepatitis C. This Phase I trial was a placebo
      controlled, randomized, dose escalating study, which evaluated the safety,
      tolerability and antiviral activity of single and multiple doses of XTL-2125.
      The study enrolled 56 patients into seven cohorts comprised of eight patients
      each (of which two are placebo patients). Each patient received a single dose,
      followed by a 14-day multi-dosing regimen commencing one week after the single
      dose administration. The highest daily multi-dose regimen that was evaluated
      in
      the trial was 1800mg per day (600mg three times per day).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      analysis of the data indicates that XTL-2125 was generally well tolerated.
      However, HCV-RNA viral load reductions in patients treated with XTL-2125 were
      not significantly different from those observed in the placebo group. Based
      on
      these results, XTL has decided to suspend further development of XTL-2125.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL&#8217;s
      CEO, Ron Bentsur, commented: &#8220;The completion of this Phase I trial concludes our
      research on the XTL legacy compounds that we inherited. Through an aggressive
      business development effort, XTL&#8217;s new management team has successfully
      reinvented the company&#8217;s product portfolio - with Bicifadine as a lead product
      in late stage clinical development, and the XTL-DOS program, which is emerging
      as a very promising program in Hepatitis C. We look forward to an exciting
      rest
      of 2007, with the initiation of a late-stage clinical trial with Bicifadine
      in
      chronic neuropathic pain, and the initiation of IND-enabling studies with a
      novel hepatitis C inhibitor from the XTL-DOS program. We will also continue
      to
      opportunistically seek to broaden our portfolio through the in-licensing and
      acquisitions of additional clinical stage products.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the acquisition, development and
      commercialization of therapeutics for the treatment of neuropathic pain and
      hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine
      reuptake inhibitor, for the treatment of neuropathic pain. XTL is also
      developing several novel pre-clinical hepatitis C small molecule inhibitors.
      &#160;XTL also has an active in-licensing and acquisition program designed to
      identify and acquire additional drug candidates. XTL is publicly traded on
      the
      NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE:
      XTL).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      +1-(845)-267-0707 ext. 225</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Cautionary
      Statement</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Some
      of the statements included in this press release, particularly those
      anticipating future performance, clinical and business prospects for our
      clinical compound for neuropathic pain, Bicifadine, and for our pre-clinical
      compounds for hepatitis C from our XTL-DOS program, growth and operating
      strategies and similar matters, may be forward-looking statements that involve
      a
      number of risks and uncertainties. For those statements, we claim the protection
      of the safe harbor for forward-looking statements contained in the Private
      Securities Litigation Reform Act of 1995. Among the factors that could cause
      our
      actual results to differ materially are the </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>following:
      our ability to start a clinical trial with Bicifadine in 2007; our ability
      to
      successfully complete cost-effective clinical trials for the drug candidates
      in
      our pipeline which would affect our ability to continue to fund our operations
      with our available cash reserves, our ability to meet anticipated development
      timelines for the drug candidates in our pipeline due to recruitment, clinical
      trial results, manufacturing capabilities or other factors; and other risk
      factors identified from time to time in our reports filed with the Securities
      and Exchange Commission and the London Stock Exchange, including our annual
      report on Form 20-F filed with the Securities and Exchange Commission on March
      23, 2007. Any forward-looking statements set forth in this press release speak
      only as of the date of this press release. We do not intend to update any of
      these forward-looking statements to reflect events or circumstances that occur
      after the date hereof. This press release and prior releases are available
      at
      http://www.xtlbio.com. The information in our website is not incorporated by
      reference into this press release and is included as an inactive textual
      reference only. </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>XTL
              BIOPHARMACEUTICALS LTD.</strong></font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:&#160;June
              6,
              2007</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font size="2">/s/ Ron Bentsur</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="50%"><font size="2">Ron
              Bentsur </font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
                Executive
                Officer</font>&#160;</div>
            </td>
          </tr>

      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>xtlbio.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 xtlbio.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!L`/X#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#WXG%+4%U>
M6]E`T]Q*L<2_>9N`/K60/&OAIB0-:LR1UQ*.*$F]A-I;FZ<#)_.N#\6?%/2?
M#5R;15:YN!U$>"!]:Z)/$.E:A!-%IVH6\\VPG8C@GI7RCJSSR:M=-<AA-YAW
M!A@BNC#454D^;H8UZW)'W3Z2\(?$K2O%5P]JN8+@*#MDP-WT]:[8`"OD'PT\
MZ>)=-:V4F43K@+U/-?4S^)=*L4CBU'4+>WN"@+(\@!%/$T8PG[H4*KG&\C9H
MK`_X3;PU@?\`$ZLSGI^]'-7KK7=+L;>.XNKZ&**7[C.V`U<[36YLFFKHT:*P
M3XT\-A2QUFS`'7,HH_X33PU@'^VK+#=/WHYHY7V%S1[F]16`WC;PP&"MK=D&
M/0&44[_A-/#><?VS9Y_ZZBBS6X^9=S=H/3FL/_A,O#G_`$&;/_OZ*3_A,O#G
M_09L_P#OZ*+,7-'N;@51VI>E8)\:^&@6']MV7R\G]Z.*U[2\M[ZV2XM9DFA?
M[KH<@T--;C33V)Z***0PHI'8(A9C@`9-98\0:;YA3[;!D-MV[QG.<=*:BWLB
M7)1W9JT4@(8`@Y!Y%+2*"BBB@`HJM=:A:V2AKF:.)3W=MH_6H[35K&^<I;74
M,S#J(W#8_*JY96O;0GGC>U]2[130W.#3JA.Y04444P"BBB@"M?64&H64MK<J
M&BE7:PQZU\L>.?#3>&?$=S9[!Y!<M"V.2IY_3I7U?M&,5QGQ(\*1>(_#<[1Q
M*;R!"T3=_4C-;T*BA/78RK4^>-CYR\.ZU/X>UN#4+;[R'#+G`93UKV+5OAK9
M^.EBU_3[S[))<J#(FS<N0,=.*\,FB>"9XI!AT.&'H:]?^#'BX6SRZ#=2-L8^
M9$S'(';:/2NS$0<5SPW..@TWR3-*Q\":=\.+:XU^]N_ML\,9\E"NP%NOY\5X
M_P"(=<G\1:O+J%PH5G/"CG:/2N]^+_C%-8U%=(M&)M[9LNRG`9NWUKS:QLI]
M1O(K6V0O+(V%44Z,6USU`KV3Y('6?#;PB/$_B*/[0A-G!EI"/4=*[SXXVZ6^
MAZ5$BJL:2%0!]*]$\(>&[;PWHEM:QQJ)Q&#(X');'-:6IZ+INLQI'J-G#<HA
MRJRH&`KCG63J\]M#JC1M3Y.Y\<8'H*,#T%?6G_"!^%_^@'8_]^16%XS\&^';
M/PI>W%MH]G%+&N5=8@"*Z8XJ$I)<ISO"-)NY\T8'H*,#T%.<`.P'0&O9/@]X
M>TC6=.N6U#3[:X9#P9(PQZUT59QA'F:.>$'*?*>,X'H*,#T%?6G_``@GA;MH
M5C_WY%</\4_"^AZ5X3-Q8Z7:V\H8C?'&%/2N>.*A)VY3>>%<8N5SP/:/05]3
M_##'_"O],PH`VD8'UKY9KZF^&'_)/]-^C?\`H1HQD4HIHK![LZX'-+117G'<
M5[\D:?<$=?+/\J\-D8/KLBN2`9L$Y]Z]QU`9T^X_ZYM_*O"Y"1KTA4'=YQVX
M]<UZ67Q34KGAYQ)J5.SZGO-O_J$^@J2J$VI6FGVL;7,P1=N>?I6,WQ`T!9-O
MVAL`X+;#C^5<2I3E=Q1ZTJ]*&DY)?,ZBBLJP\1Z7J0!MKI6!Z9!'\ZTPW(&1
MG&:S<6MS2,XS5XNYQGQ#L+F]L+<6Z;R'Y&?8UF?#S3;JQO[@SQ;`P&.]=[?7
MUO9(C7#`;C@<9J*QU"RNPZVS@E3\VT8Q72J\O8^SMH<,\+3EBE6YM5T-"BD4
MY&:IWFJ6>G1;[F81K[US)-Z([W)15V7:*YB7Q]H,3[1<.W'4(:L6GC+1;PJL
M=R0[=%92/YUHZ%5*[BS%8J@W;G7WF_134<2#*D$>U.K(W$&<<T$`C!&0:6@Y
MQQ0!\]?&'PC%H^K1:G8PLL%UDS8Z!_7VS7FEM<S6=PEQ;N4E0Y5AVKZP\7II
M+^'KH:OL^S!"27['MBODZ?:9Y-GW-QV_3->GA)N4;,\_%049<R&R.TLC2.2S
M,<DGN:]L^#?@N)83X@O8SYV<0`]`/7\:\=TJ6TAU6VEOHS):K(#(H[BOK/0+
MC3[G0K:;3%C6U9`55!@"EC)N,.5#PL$Y79J*5.<'-.IJ+M!XQDTZO-1WA7.>
M._\`D3=1_P"N=='7.>._^1-U'_KG5TOC7J3/X6?)[_ZQOJ:]U^!7_(+O?K_4
MUX4_^L;ZFO=?@5_R"[WZ_P!37H8O^$>?0_C?>>O5Y[\8_P#D2V_W_P"AKT*O
M/?C'_P`B6W^__0UY]/XT=M;^&SYLKZF^&'_)/]-^C?\`H1KY9KZF^&'_`"3_
M`$WZ-_Z$:[\;\"]3FP?4Z^BBBO-.XKW_`/R#[C_KFW\J\&O)&AU>65>JREA^
M!KWC4/\`D'7'_7-OY5X+J'SZI.#_`,]"/UKU<L^T?/9]M`W1'J/B^_0C=A%"
M@Y.T#_'GVK;_`.%:2&'B8"3'7=QFNL\*:='8Z)`@CPQ&2<8)K='NN*PJ8R<7
MRT]$CJHY92J0YZRNV>%:EIM_X;U!4=RK_>1EZ$9KTOP;XE?6+<P7!4S1CJ.X
MJSXOTNWOM)D,D:[P/E?'(->;^#;J2V\3VZ(V(V8JR]L5TMK%4&VO>1QQ4LOQ
M:@G>$CKOB:Q_LRU(/_+7''TK-^&))O+W))^5>IK1^)N#I-GC_GI_2L[X8'%Y
M>G_96I@E]2;M_5S2JW_:L5?H=QXAU==&TUK@XR,`#'>O)+B_U+Q/J6%)+.?N
M@<+V_P`FMKXA:I]IODM5)V(,D=LUO?#O2HETH7K1@O(QPQ'IQ2I1CAZ/M6M6
M*O.>,Q?U>+M%;F=:_#>65%:ZGP3U*GIQ[UDZ]X*O-)7SK;?+$!SCDUZ^P/X4
MR6)9H7B<9#`UA',*REKL=E3*,/*-DK,\K\*>,KJTO(;*[?=;L=HW#D'ZUZL6
M^0,#UKPOQ!IS:5K,T97"[RRC&.,\5ZGX9U$:AH$!W[V488DUKCJ4>558=3#*
ML144I8>J]5L='D<^U!8!=W:D`7@9KAOB;XOM_#_AZ>U60_;;F,I$`.F>#].*
M\Z$7)V1[4FHJ[/.OC'XO&I:DFCV4H:VA7,Q'=\]/PQ7EUO;RW4Z00H7D<X51
MW-,=VD<N[%F8Y)/>O9O@UX.\R-O$%W&"IRD"MW]\?6O5NL/3/.5Z]3R/&65D
M<JP(8'!!KUWX.>,A9W+Z'>S?NY6W0ECT..153XQ^$1I=_'K5L@6"Y;9(%_A?
MMQ[_`-*\OAFD@E66)V1U(((.*;M7IZ"3="9]I`Y`-%<A\/O%UOXHT&']Y_I<
M*!9E/7('6NOKR6G%V9Z2::N@KG/'G'@S4?\`KG_6NCKF_'O'@O4?]P?SJJ;M
M-,4_A9\H/_K&^IKW7X%?\@N]^O\`4UX4_P#K&^IKW7X%?\@N]^O]37H8O^$>
M?0_C?>>O5YY\8_\`D2V_W_Z5Z$#D5Y]\8L?\(6W^^?Y&O/I:S1VUOX;/FROJ
M;X8?\D_TWZ-_Z$:^6:^FOAOJMC:^`]-2:YC1L-P6'K7?C$W!6.;!O5G=T5FC
M7M+)_P"/V+\6%+_;VE_\_L/_`'T*\T[BS?\`_(/N/^N;?RKP>YC,NM21KU:8
M@?G7L]]K>FR64RK>Q9*$`;NO%>*WQ']J2MD8,A(/MFO5RW[1\_GO_+OU/>K!
M!'8P`$'"#D=.E6>HK-T*Z6[T>WE3&"H_*KQ!,@QP!7F35I.Y[M-IP316U-0=
M/F#<_(W\J\5T`E?$$)!((8\BO6?%=_#8:/(TCE2>FWK7F7@ZUDN/%=OM7Y59
MF)]J]/!+EH3;/#S/W\52C'>YUGQ+(;1[(C^__2L[X9?\?=[_`+JUI?$U0NDV
M:CH)/Z5G?#`9O+T?[*TX?[B_ZZBJ_P#(UCZ'.>+&E;7KCS%QAR$_W:]2\%*B
M^%;0)T^;\\G->?>/K"2WU@3;3Y3+U/KFNP^'VH1R^'DMC)F2-F&#UZY_K1B?
M>PL6N@L!^[Q]2,MV=<65LKFE^ZOK@4@&2,]J21]HW9X&<UY*U/H7H>2_$0?\
M3_/JBUTOP_P-%.1QQ_,UQ'BO4%U+7)2A)"G9D^Q/^->C^#K(V/AV'S$`9R2>
M.1[5ZN)]S#1B]V?.X*U7'3J1V1N:C?0Z99R75PP6*(;F)-?+7C7Q))XG\1W%
MYD^0&VPJ3T45]0:UH=EKUD;2^1GA;[RARN?RKE5^#_@U<`:8X4<#%P_'ZUQ8
M>I"F[R1[E:G*HK)G@/A?PY<>)M8BLH.%)!=O05]5Z1ID>DZ3!8PC"1+BL[P_
MX+T+PP\C:59^4TARS%BQ_,UO8;=RWO2KUO:OR"C25->9C>*?#L'B70I]/F`!
M<?(_]UNQKY8U[19]`U>?3[C):,_*^,;AZU]A5S6N^`O#WB2[6ZU*R\R51C<K
ME/Y56'Q'LM'L*O1]HM#YY\`^*CX3\1QW;AFMI!Y<J*>H/0U]2VMREW;QSQ'*
M.,@BN*/PA\'`\:;)[?Z0_P#C75Z5I-MHMDMM;>8(QT#N6Q^=3B*L:DN9(=&G
M*"LV7P<US?CX@>"]1)Z;!_,5TF>,U4U/3[;5["6QNX]\$HPZYQFL4[-,UDKI
MH^.'_P!8WU->Z_`O/]EWN/4?S-='_P`*@\&C_F&R'_MX?_&NA\/^%M*\,Q/'
MID!A5^HWEL_G777Q$:D.5(Y:>'<9\S9M8KSOXR`GP8=IP=_]*]$K+UWP_IWB
M.R%IJ4/G0AMP7<1S^%<L)<LD^QT5(N46CX^J47,Z@`3R`#@`.>*^EC\(O!K,
M2=.?/M,X_K1_PJ#P9_T#9/\`P(?_`!KT/KE-[HX_JDNY\T_:KC_GXE_[[-+]
MJN/^?B7_`+[-?2O_``J#P9_T#9/_``(?_&@_"'P6.NG2?^!#_P"-+ZW2_E#Z
MI+N?-:7,YD7=<S*I/)WDX%>@Z;;F]$45NVXE>"_&<=?6O4Q\(O!JG*Z:^X>L
M[G^9K2M?`VBV4Z2PP,K)]WYS6E/'4H)V1Q8S+*E?E2>QQ^@^*)O"X>PNXC(J
MMGA@",XKHF^).G+"9/LMQNQG!QC\\UMZGX7TS5`7FMT\TKMWD<USP^'%LK\W
M!9.RD<5E[3#5/>FM32-+'4%R4VFNAR/B7Q)/XBN%6)3'".B@YS[GT^E=QX&\
M/OIMJ;NX/[Z7MC&!6CIG@[2=/4$6RM(#G<>>:W@`@P,8'05%?%1=-4Z:LC3"
M8"<:KKUW>3.%^)__`""[7_KI_2LWX8?\?EY_NK_.N[UC1K/6X4BNXRX4Y&&(
MQ46C>'-/T9W:SB9&888EB<TXXJ"PWLNH3P-26-6(OHBKXOT7^U]*9$P)%^93
MC->66%[>>&=7.]"'C/SQ[L9KW7`.1UK(U3PSI>JEGN+93(0`7'!X]Z6&Q2IQ
MY*BO$,=E[K356D[21ST'Q,TYQMDMK@/CL`1_.LC7?B`;NW:&RB:,MD%F(S^0
MK4F^'%L\H:"8PJ#RNW.1^-7;/P#I<$V^:,28Z#)K53P<'S)&,H9C4CR-I>9Q
M'AKPO=:M>K*X"1`AR2,Y&>E>PK`J0K&H`"TVUM(+2,1P1+&@X`%3\Y]JY<1B
M77E=['=@L%'"PLMWN%%%%<YV!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`&!Z4444`%%%%`!1@>E%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
..%%%`!1110`4444`?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
